GXDX: Here's my semi-annual pump for NGNM. Neogenomics is a similar genetics testing firm that is about two years behind GXDX in size and revenues. They claim to have excellent turnaround times and tech only FISH, allowing the pathologists to collect more revenue. FY 2008 was $20 million, 74% YOY growth from 2007.
A penny stock now, but has consistently put 15% QOQ growth for the last two years.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.